Porphyria Cutanea Tarda

🧠 Standard of Care & Symptoms

Porphyria Cutanea Tarda (PCT) is the most common form of porphyria. It is a metabolic disorder resulting from a deficiency in heme biosynthesis, causing severe cutaneous phototoxicity upon exposure to sunlight.

• Presentation: Key clinical signs.
  • *Skin Fragility & Blistering:* Subepidermal, tense blisters and deep erosions occur primarily on sun-exposed areas, classically the backs of the hands and the forearms.
  • *Hyperpigmentation & Hypertrichosis:* Skin darkening on the face and neck, accompanied by fine, excessive hair growth (hypertrichosis) around the temples, cheeks, and forehead.
  • *Milia & Scarring:* Ruptured blisters heal slowly, leaving small white epidermal cysts (milia), pigmentary changes, and superficial scarring.
  • *Pseudoscleroderma:* Long-term disease can cause skin thickening and hardening on the neck and chest, resembling scleroderma.

🧬 Diagnostics & UROD Pathophysiology

Diagnosis requires measuring elevated levels of uroporphyrins in the blood, urine, and stool, alongside screening for underlying hepatic triggers.

• Diagnostic Markers: Key criteria.
  • Plasma Porphyrin Profile: Reveals elevated total porphyrins with a highly characteristic fluorescence emission peak at **618 nm to 620 nm** when excited by light.
  • Urinalysis: Demonstrates a marked increase in highly carboxylated porphyrins, particularly **uroporphyrin** and **heptacarboxylporphyrin**. Urine may show a pink-to-red discoloration under a Wood's lamp (UV light).
  • Iron & Hepatic Panels: Elevates serum ferritin and transferrin saturation. Screening is mandatory for **Hepatitis C (HCV)**, hereditary hemochromatosis gene (*HFE*) mutations, and liver dysfunction, as these are key acquired triggers.

Pathophysiology of UROD Deficiency

The phototoxic lesions in PCT are caused by a block in the biosynthetic pathway of heme:

• UROD Enzyme Inhibition: PCT is caused by a ≥50% reduction in the activity of **Uroporphyrinogen Decarboxylase (UROD)**, the fifth enzyme in the heme pathway. In sporadic PCT (Type I, 80% of cases), UROD inhibition is restricted to hepatocytes and is driven by oxidation from hepatic iron overload.
• Porphyrin Accumulation: The block at UROD leads to the accumulation of hydrophilic uroporphyrinogen and heptacarboxylporphyrinogen. These leak from the liver into the bloodstream and deposit in the skin.
• Phototoxicity (UVA-Soret Band): Upon absorption of long-wave ultraviolet light (UVA, ~400 nm, the Soret band), the accumulated porphyrins are excited to a triplet state. They interact with molecular oxygen, generating **singlet oxygen** and other reactive oxygen species (ROS) that cause lipid peroxidation, lysosomal damage, and subepidermal cell cleavage.

💊 Phlebotomy & Antimalarial Therapies

Treatment focuses on reducing iron stores in the liver and accelerating the excretion of accumulated porphyrins.

Therapeutic Phlebotomy (First-Line)

• Iron Depletion Protocol: Repeated phlebotomy (removal of 450 mL of blood every 2 to 4 weeks) is the gold standard. Removing iron reverses the oxidation and inactivation of the UROD enzyme in hepatocytes. Phlebotomies are continued until the serum **ferritin** drops to the lower limit of normal (approximately 15 to 20 ng/mL).

Low-Dose Antimalarials (Alternative First-Line)

• Low-Dose Chloroquine or Hydroxychloroquine: Deployed in patients who cannot tolerate phlebotomy (e.g. due to severe anemia or cardiovascular disease). Low doses (e.g. **Hydroxychloroquine 100 mg twice weekly**) form water-soluble complexes with hepatic porphyrins, promoting their rapid clearance and urinary excretion. Standard high doses must be strictly avoided, as they can precipitate acute hepatotoxicity.

Trigger Elimination

• Avoidance of Exogenous Triggers: Patients must strictly cease alcohol consumption, discontinue estrogen therapies (e.g. oral contraceptives or hormone replacement), and receive antiviral treatment if positive for Hepatitis C.

🔬 Active Clinical Trials

Clinical trials are currently evaluating novel oral iron chelators, targeted siRNA silencing therapies, and genetic studies.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Porphyria Cutanea Tarda, establish these clinical care pathways:

1. Confirm Serum Porphyrin Peak: Ensure your plasma profile shows the signature emission peak at 618-620 nm to rule out other porphyrias.
2. Screen for Associated Conditions: Get tested for Hepatitis C, genetic Hemochromatosis (*HFE* mutations), and liver enzymes.
3. Initiate Phlebotomy or Low-Dose Hydroxychloroquine: Coordinate with a hematologist or dermatologist to establish your iron depletion plan.
4. Strictly Eliminate Triggers: Immediately stop alcohol intake and discuss alternative birth control/hormone options to stop estrogen therapies.

❓ Patient FAQ

Q: Why does the urine turn red or dark in PCT?
A: The urine turns dark or reddish-brown due to the high concentration of uroporphyrins being excreted by the kidneys. When exposed to ultraviolet light (like a Wood's lamp), the porphyrins in the urine emit a bright pink-red fluorescence.

Q: Can sunscreen prevent the blisters in PCT?
A: Regular sunscreens that only block UVB or short-wave UVA are not effective. Excitation of porphyrins is driven by visible light and long-wave UVA around 400 nm (the Soret band). Patients must use physical block sunscreens containing **zinc oxide** or **titanium dioxide**, wear sun-protective clothing, and avoid midday sun exposure.